Pancreatic Cancer
📧 Sign up to get email alerts when something new happens for Pancreatic Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer [NA]
Clinical trial update on radiopaque hydrogel spacer used during radiotherapy for pancreatic cancer; study completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer [Phase 2]
Phase 2 clinical trial evaluating mFOLFIRINOX as first-line chemotherapy in Chinese patients with metastatic pancreatic cancer has completed…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. [Phase 2]
Phase 2 trial assessing the efficacy and safety of postoperative mFOLFIRINOX as adjuvant chemotherapy for resectable pancreatic cancer in Ch…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer [Phase 1, Phase 2]
Phase 1b/2 trial evaluating tarextumab (OMP-59R5) in combination with nab-paclitaxel and gemcitabine in previously untreated stage IV pancre…
-
FDA approval · 2023-02-03FDA Approved: ONIVYDE — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for ONIVYDE (liposomal irinotecan), submitted by Ipsen Biopharmaceuticals, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer [Phase 2]
Phase 2 trial evaluating the combination of an anti-PD-1 antibody with chemotherapy in metastatic pancreatic cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition [Phase 1]
A Phase 1 trial update investigates inhibiting SGLT2 as a potential approach for pancreatic cancer, with the study completed and results pos…
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer [Phase 3]
A Phase 3 trial evaluating mistletoe therapy in primary and recurrent inoperable pancreatic cancer has been completed.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma [Phase 1, Phase 2]
Clinical trial update for durvalumab plus CV301 with maintenance chemotherapy in metastatic colorectal or pancreatic adenocarcinoma; study s…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer [Phase 2]
Phase II trial update investigating sequential AG and FOLFIRINOX as neoadjuvant therapy in patients with resectable pancreatic cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-03Clinical Trial Update: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas [Phase 3]
Phase 3 trial comparing FFX to CPI-613 with mFFX in metastatic pancreatic adenocarcinoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer [Phase 2]
Phase 2 trial evaluating a PD-1 inhibitor with or without a vitamin D analog for maintenance therapy in pancreatic cancer has completed enro…
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating irreversible electroporation (IRE) for locally advanced pancreatic carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety trial of GEN1029 (HexaBody-DR5/DR5) in malignant solid tumors (termina ted; results posted in 2022).
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer [Phase 2]
A Phase 2 clinical trial evaluating concurrent chemoradiotherapy with immunotherapy in potentially resectable pancreatic cancer.
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine [Phase 2]
Phase 2 trial evaluating nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: Nutrition and Pharmacological Algorithm for Oncology Patients Study [Phase 4]
Phase 4 trial update for a nutrition and pharmacological algorithm in oncology patients; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-11-01Clinical Trial Update: A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer [Phase 2]
Phase 2 trial update of GSK2256098 with trametinib in advanced pancreatic cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer [Phase 3]
Phase 3 trial evaluating FOLFIRINOX with or without SBRT in locally advanced pancreatic cancer has completed and results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-10-27Clinical Trial Update: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma [Phase 2]
Phase 2 trial update on neoadjuvant modified FOLFIRINOX with stereotactic body radiation therapy in borderline resectable pancreatic adenoca…
-
FDA approval · 2022-10-20FDA Approved: PACLITAXEL — Original Application (BluePoint Laboratories)
FDA approves paclitaxel as a generic product under an original application from BluePoint Laboratories.
-
FDA approval · 2022-10-18FDA Approved: FLUOROURACIL — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved a supplemental application for fluorouracil submitted by Taro Pharmaceuticals U.S.A., Inc., approving changes to the product’s …
-
CLINICAL_TRIALS trial_result · 2022-10-13Clinical Trial Update: A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer [Phase 1]
Phase 1 dose-escalation trial evaluating SBRT after induction chemotherapy for locally advanced pancreatic cancer is completed with results …
-
CLINICAL_TRIALS trial_result · 2022-10-10Clinical Trial Update: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma [Phase 2]
Phase 2 trial comparing Nanoliposomal Irinotecan (Nal-IRI)–containing regimens to nab-paclitaxel plus gemcitabine in previously untreated me…
-
CLINICAL_TRIALS trial_result · 2022-10-04Clinical Trial Update: Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy [Phase 1]
Phase 1 trial evaluating a neoantigen DNA vaccine in pancreatic cancer patients after surgery and adjuvant chemotherapy; study terminated wi…